Correlation of a brief perceived stress measure with nonadherence to antiretroviral therapy over time

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 5, 2005, Pages 590-597

  French, Tyler ^a   Weiss, Linda ^b   Waters, Mark ^a   Tesoriero, James ^a   Finkelstein, Ruth ^b   Agins, Bruce ^a  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

Adherence; AIDS; Highly active antiretroviral therapy (HAART); HIV; Perceived stress

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DISTRESS SYNDROME; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TREATMENT FAILURE; VALIDATION PROCESS; VIRUS RESISTANCE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HOUSING; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SELF CONCEPT; STRESS, PSYCHOLOGICAL; SUBSTANCE-RELATED DISORDERS;

EID: 17144430160     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000135960.88543.8d     Document Type: Article

References (55)

1. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29(Suppl 1):S2-S10.
2. Knobel H, Carmona A, Grau S, et al. Adherence and effectiveness of highly active antiretroviral therapy. Arch Intern Med. 1998;158:1953.
3. Bangsberg D, Hecht F, Charlebois E, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
4. Maher K, Klimas N, Fletcher MA, et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs medical center. J Acquir Immune Defic Syndr. 1999; 22:358-363.
5. Paterson DL, Swindells S, Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
6. McNabb J, Ross JW, Abriola K, et al. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
7. Le Moing V, Chene G, Carried MP, et al. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr. 2001;27:372-376.
8. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15:1181-1183.
9. Knobel H, Guelar A, Carmona A, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS. 2001;15:193-199.
10. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000;30(Suppl 2): S177-S184.
11. Pomerantz RJ. Primary HIV-1 resistance: a new phase in the epidemic? JAMA. 1999;282:1177-1179.
12. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med. 1995;122:401-408.
13. Erice A, Mayers DL, Strike DG, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328: 1163-1165.
14. Imrie A, Beveridge A, Genn W, et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J Infect Dis. 1997;175:1502-1506.
15. Hecht FM, Grant RM, PetroPoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-311.
16. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
17. Sackett D, Snow J. The magnitude of compliance and non-compliance. In: Haynes R, Taylor D, Sackett D, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press; 1979:11-12.
18. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23: 360-361.
19. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
20. Bouhnik D-A, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr. 2002;31 (Suppl 3):S149-S153.
21. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
22. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26:195-205.
23. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001;39:1151-1162.
24. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
25. Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481-1496.
26. Singh N, Herman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
27. Roca B, Gomez CJ, Arnedo A. Adherence, side effects, and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients. J Infect. 2000;41:50-54.
28. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000;30(Suppl 2): S96-S116.
29. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
30. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92.
31. Tesoriero J, French T, Weiss L, et al. Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the Treatment Adherence Demonstration Project. J Acquir Immune Defic Syndr. 2003; 33:484-493.
32. Malcolm S, Ng J, Rosen R, et al. An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care. 2003;15:251-261.
33. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31:S123-S127.
34. Gebo KA, Keruly J, Moore RD. Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med. 2003;18(2):104-111.
35. Evans DL, Ten Have TR, Douglas SD, et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry. 2002;159:1752-1759.
36. Burack J, Barrett D, Stall R, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568-2573.
37. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1466-1474.
38. Leserman J, Jackson ED, Petitto JM, et al. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 1999;61:397-406.
39. Leserman J, Petitto J, Gu H, et al. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med. 2002;32:1059-1073.
40. Golub ET, Astemborski JA, Hoover DR, et al. Psychological distress and progression to AIDS in a cohort of injection drug users. J Acquir Immune Defic Syndr. 2003;32:429-434.
41. Bing E, Burnam A, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-728.
42. Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis. 2001;33:847-856.
43. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765.
44. Cohen M, Hoffman R, Cromwell C, et al. The prevalence of distress in persons with human immunodeficiency virus infection. Psychosomatics. 2002;43:10-15.
45. Morrison M, Petitto J, Ten Have T, et al. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry. 2002;159:789-796.
46. Cruess DG, Evans DL, Repetto MJ, et al. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry. 2003;54:307-316.
47. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001; 158:725-730.
48. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
49. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Social Behav. 1983;24:385-396.
50. Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In: Spacapan S, ed. The Social Psychology of Health: Claremont Symposium on Applied Social Psychology. Newbury Park: Sage; 1988:31-67.
51. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. AIDS Care. 2000;12:255-266.
52. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
53. Wagner JH, Justice AC, Chesney MA, et al. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol. 2001;54:S91-S98.
54. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112-1118.
55. DiMatteo RM, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med. 2000;160:2101-2107.